Categories

Mental Health Month, Depression and GeneSight®    The GeneSight® genetic test has produced exciting news for patients diagnosed with depression.  A landmark study showed that the GeneSight Test led to significant improvement in mental health outcomes for patients with major depressive disorder (MDD).  Read the full news release here.  This exciting, new data for GeneSight was presented at…

Continue Reading

ColonCancerPoster_Thumbnail

In hereditary colon cancer, knowledge is power!  During the month of March, Myriad Genetics is demonstrating a strong commitment to preventing hereditary colon cancer as part of National Colorectal Cancer Awareness Month.  Colon cancer is third most commonly diagnosed cancer in both men and women in the United States and kills one person every 10 minutes. More than 140,000…

Continue Reading

The U.S. Food and Drug Administration (FDA) has approved BRACAnalysis CDx® for use as a companion diagnostic to identify patients with HER2- metastatic breast cancer who are candidates for treatment with AstraZeneca’s PARP inhibitor, Lynparza®(Olaparib). BRACAnalysis CDx is the only FDA-approved test for use in this important indication. The approval of BRACAnalysis CDx underscores the need for  patients with…

Continue Reading

It is estimated that 19 million people suffer from “year round” depression. If every American with depression lived in one state it would be the country’s fifth largest state. For many of these people, their depression will get worse in the winter months. Additionally, approximately 11 million Americans suffer from a severe winter form of…

Continue Reading

Shortly after I was born, my father was diagnosed with Hodgkin’s lymphoma and he passed away when he was just 29 years old.  Losing my dad when I was so young is what ultimately led me to becoming a cancer genetic counselor focusing on cancer prevention…which begins with knowing your family history. I came to…

Continue Reading

At Myriad, we are committed to defeating breast cancer and we know that decisions matter when it comes to breast cancer. We have several genetic tests that can help women with breast cancer, but can also help others with preventing breast cancer. Currently, myRisk now with riskScore, EndoPredict, BRACAnalysis CDx, and myChoice HRD are genetic…

Continue Reading

When diagnosed with prostate cancer, genetic precision can guide decisions between patients and their doctors. Click below to learn more and download this infographic. Learn how a hereditary cancer risk assessment is an important option for prostate cancer patients during Prostate Cancer Awareness Month.  

Continue Reading

At Myriad Genetics, with our privacy policy, we believe that patients should have access to their protected health information, including their genetic test results.  We believe that access to such genetic information enables the patient to make more informed and educated healthcare decisions.  Myriad has a number of resources to make it easier for patients…

Continue Reading

BioEYES Logo

Myriad Genetics was proud to support Project BioEYES and help deliver STEM (science, technology, engineering, and mathematics) education to K-12 students throughout the Salt Lake City school district during the 2016-17 academic school year.  The local BioEYES program, which is led by the University of Utah’s Dr. Judith Neugebauer and John Anderson, taught more than…

Continue Reading

June is Men’s Health Month and it’s important to help generate awareness on education for early detection of Men’s health issues, such as prostate cancer.  Prostate cancer is the most common cancer in Men, not including skin cancer. 1 of 7 men will be diagnosed with prostate cancer in his lifetime.  To help promote prostate cancer awareness, Myriad Genetics interviewed…

Continue Reading